KR920006314A - 아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물 - Google Patents

아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR920006314A
KR920006314A KR1019910015523A KR910015523A KR920006314A KR 920006314 A KR920006314 A KR 920006314A KR 1019910015523 A KR1019910015523 A KR 1019910015523A KR 910015523 A KR910015523 A KR 910015523A KR 920006314 A KR920006314 A KR 920006314A
Authority
KR
South Korea
Prior art keywords
group
alkyl
denotes
compound
inorganic
Prior art date
Application number
KR1019910015523A
Other languages
English (en)
Other versions
KR100194823B1 (ko
Inventor
에몽-알트 자비에르
굴라우익 삐에르
프로이에또 빈센조
반 브뢰크 디디에르
Original Assignee
알링 시. 세워드
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26228221&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920006314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9011039A external-priority patent/FR2666335B1/fr
Priority claimed from FR9107824A external-priority patent/FR2678267B1/fr
Application filed by 알링 시. 세워드, 사노피 filed Critical 알링 시. 세워드
Publication of KR920006314A publication Critical patent/KR920006314A/ko
Application granted granted Critical
Publication of KR100194823B1 publication Critical patent/KR100194823B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

내용 없음

Description

아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기 일반식(1)의 화합물 또는 그의 무기산 또는 유기산과의 염.
    상식에서, -Y는·Cy-N의기[식중, Cy는 수소, 할로겐원자, 히드록실 C1∼C4알콕시, C1∼C4알킬, 트리플루오메틸 중에서 선택된 동일하거나 상이한 치환체 중의 하나로 한번 이상 치환된 페닐 또는 비치환된 페닐, C3∼C7시클로알킬기, 피리미디닐기 또는 피리딜기이다]이거나,의기[식중, Ar은 수소, 할로겐원자, 히드록실, C1∼C4알콕시, 트리플루오로메틸, C1∼C4알킬 중에서 선택된 동일하거나 상이한 치환체 중의 하나로 한번 이상 치환된 페닐 또는 피치환된 페닐, 피리딜기, 티에닐기이고, X는 0또는 1이며, X는 히드록실, C1∼C4알킬렌이 C1∼C3인 아미노알킬렌, -N-(X1)2의 기(여기서, X1기는 각각 수소, C1∼C4알킬이다),AIK의 기(여기서, AIK는 C1∼C6알킬이다),의기(여기서, AIK1은 C1∼C3알킬렌이고, AIK1'는 C1∼C3알킬이다), C1∼C4아실, -S-X2의기(여기서, X2는 수소 또는 C1∼C4알킬기이다), 또는 X는 X가 결합된 탄소원자 및 헤테로고리내에서 인접한 탄소원자와 함께 이중결합을 형성하다]이고, -m은 2 또는 3이며, -Ar'는 수소, 할로겐 원자, 바람직하게는 염소 또는 불소원자, 트리플로우로메틸, C1∼C4알콕시, C1∼C4알킬 중에서 선택된 동일하거나 상이한 치환체중의 하나로 한번 이상 치환된 페닐 또는 비치환된 페닐, 티에닐, 벤조티에닐, 나프틸, 인돌릴, C1∼C3알킬로 N-치환된 인돌릴이고, -R은 수소, C1∼C6알킬이며, -T는중에서 선택된 기(식중, W는 산소 또는 황원자이다)이고, -Z는 수소이거나, T가의 기일 경우 M 또는 OM이거나, T가의 기일 경우 M(여기서, M은 C1∼C6알킬, 방향족 고리에 할로겐, 트리플루오로메틸, C1∼C4알킬, 히드록실, C1∼C4알콕시가 임의 치환되었으며 알킬이 C1∼C3기인 페닐알킬, 알킬이 C1∼C3기인 피리딜알킬, 니프틸고리계에 할로겐, 트리플루오로메틸, C1∼C4알킬, 히드록실, C1∼C4알콕시가 임의 치환되었으며, 알킬이 C1∼C3기인 나프틸알킬, 알킬이 C1∼C3기인 피리딜 티오알킬, 스티릴, 임의 치환된 일-, 이- 또는 삼원 방향족 또는 헤테로방향족기이다.]
  2. 제1항에 있어서, Ar'가 3,4-디클로로페닐기인 화합물 또는 그의 무기산 또는 유기산과의 염.
  3. 제1항 또는 제2항에 있어서, X가 히드록실, 아세틸옥시 또는 일반식(여기서, AIK는 C1∼C6알킬이다)인 화합물 또는 그의 무기산 또는 유기산과의 염.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, R이 메틸인 화합물 또는 그의 무기산 또는 유기산과의 염.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, T가 -C=0 기 인 화합물 또는 그의 무기산 또는 유기산과의 염.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, T가 -C=0기이고 Z가 티에닐기인 화합물 또는 그의 무기산 또는 유기산과의 염.
  7. 제1항 내지 제5항중 어느 한 항에 있어서, T가 -C=0 기이고 Z가 염소와 같은 할로겐으로 이치환 될수 있는 페닐기인 화합물 또는 그의 무기산 또는 유기산과의 염.
  8. 제1항에 내지 제7항중 어느 한 항에 있어서, 라세미형 또는 거울상 이성질체형의 N-메틸-N-[4-(4-페닐-4-아세틸아미노피페리딜)-2-(3,4-디클로로페닐)부틸]벤즈아미드 및 그의 무기산 또는 유기산과의 염.
  9. (-)-N-메틸-N-[4-(4-페닐-4-아세틸 아미노피페리딜-2-(3,4-디클로로페닐)부틸]벤즈아미드 및 그의 무기산 또는 유기산과의 염.
  10. (+)-N-메틸-N-[4-(4-페닐-4-아세틸 아미노피페리딜-2-(3,4-디클로로페닐)부틸]벤즈아미드 및 그의 무기산 또는 유기산과의 염.
  11. 하기한 바를 특징으로 하는 제1항 내지 제7항에 따른 화합물의 제조방법. -a)광학적으로 순수한 형태일 수 있는 하기 일반식(Ⅱ) 또는 (Ⅱ'＂)의 유리 아민을, T가 -CO-인 일반식(Ⅰ)의 화합물을 제조하는 경우 하기 일반식(Ⅲ)의 산의 관능 유도체로 처리하거나 또는 T가 -C(W)-NH-인 일반식(Ⅰ)의 화합물을 제조하는 경우 하기 일반식(Ⅲ')의 이소(티오)시아네이트로 처리하여 하기 일반식(Ⅳ)의 화합물을 형성하고,
    [상기식에서, m, Ar', R, Z 및 W는 제1항에서 정의한 바와같고, E는 예를들면, 테트라히드로-2-피라닐 옥시 또는의기(여기서, Y는 제1항에서 정의한 바와같고 X가 히드록실일때, 이 히드록실기는 보호될 수 있다)와 같은 O-보호기이다.]-b)E가 테트라히드로피라닉옥시기인 경우, 산을 작용시켜 테트라히드로피라닐 기를 제거하며, 이 탈보호는 일반식 (Ⅱ'＂)의 화합물을 수득하기 위하여 임의적으로 일반식(Ⅱ)의 화합물 상에서 직접 행한 후 일반식(Ⅱ)의 화합물 상에서 직접 행한후 일반식(Ⅲ) 또는 (Ⅲ')의 화합물로 처리하고, c)수득한 하기 일반식(Ⅴ)의 N-치환 알칸올아민을 메탄술포닐 클로라이드로 처리하며,
    d)수득한 하기 일반식(Ⅵ)의 메실레이트를 하기 일반식(Ⅶ)의 2급 아민으로 처리하고,
    (식중, Y는 제1항에서 정의한 바와같다) e) 적당하다면, X로 나타내는 히드록실을 탈보호시킨 후, 수득한 생성물을 그의 염으로 임의로 전환시킨다,
  12. 제1항 내지 제7항중 어느 한 항에 따른 일반식(Ⅰ)의 화합물을 유효성분으로서 함유하는 약제학적 조성물.
  13. 제12항에 있어서, 활성 성분을 하나 이상의 약제학적 부형제와 혼합한 복용단위인 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910015523A 1990-09-05 1991-09-05 아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물 KR100194823B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9011039A FR2666335B1 (fr) 1990-09-05 1990-09-05 Arylalkylamines, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR9011039 1991-06-25
FR9107824 1991-06-25
FR9107824A FR2678267B1 (fr) 1991-06-25 1991-06-25 Arylalkylamines, procede pour leur preparation et compositions pharmaceutiques les contenant.

Publications (2)

Publication Number Publication Date
KR920006314A true KR920006314A (ko) 1992-04-27
KR100194823B1 KR100194823B1 (ko) 1999-06-15

Family

ID=26228221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910015523A KR100194823B1 (ko) 1990-09-05 1991-09-05 아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (27)

Country Link
US (2) US5236921A (ko)
EP (1) EP0474561B1 (ko)
JP (1) JP2620435B2 (ko)
KR (1) KR100194823B1 (ko)
AT (1) ATE174332T1 (ko)
AU (1) AU657272B2 (ko)
BR (1) BR9103802A (ko)
CA (1) CA2050639C (ko)
CZ (1) CZ285994B6 (ko)
DE (1) DE69130597T2 (ko)
DK (1) DK0474561T3 (ko)
ES (1) ES2127722T3 (ko)
FI (1) FI98457C (ko)
GR (1) GR3029435T3 (ko)
HK (1) HK1005290A1 (ko)
HU (2) HU222351B1 (ko)
IE (1) IE913082A1 (ko)
IL (1) IL99320A (ko)
LV (1) LV10606B (ko)
MY (1) MY142065A (ko)
NO (1) NO177226C (ko)
NZ (1) NZ239661A (ko)
PL (1) PL167994B1 (ko)
PT (1) PT98849B (ko)
RU (1) RU2070196C1 (ko)
SG (1) SG47703A1 (ko)
UA (1) UA27224C2 (ko)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830863A (en) * 1988-06-20 1998-11-03 Merrell Pharmaceuticals Inc. Neurokinin A antagonists
US6218364B1 (en) 1988-06-20 2001-04-17 Scott L. Harbeson Fluorinated neurokinin A antagonists
ZA906188B (en) * 1989-08-10 1991-06-26 Merrell Dow Pharma Cyclic neurokinin a antagonists
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
FR2688218A1 (fr) * 1992-03-03 1993-09-10 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) * 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
US5391819A (en) * 1992-09-30 1995-02-21 Merck & Co., Inc. Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
US5583134A (en) * 1992-09-30 1996-12-10 Sanofi 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
ATE169001T1 (de) * 1993-01-28 1998-08-15 Merck & Co Inc Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
CA2160462C (en) * 1993-05-06 1998-12-15 Timothy P. Burkholder Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
AU7947594A (en) * 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
GB9325074D0 (en) * 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
ATE170174T1 (de) * 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
GB2287404A (en) * 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717477B1 (fr) * 1994-03-18 1996-06-07 Sanofi Elf Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717478B1 (fr) * 1994-03-18 1996-06-21 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2718136B1 (fr) * 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9408872D0 (en) * 1994-05-03 1994-06-22 Zeneca Ltd Heterocyclic compounds
BR9508375A (pt) * 1994-07-12 1997-10-28 Lilly Co Eli Antagonista de receptor de taquicinina heterociclica
WO1996004266A2 (de) * 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
MX9701305A (es) 1994-08-25 1998-05-31 Merrell Pharma Inc Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) * 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
CA2162786A1 (en) * 1994-11-22 1996-05-23 Philip Arthur Hipskind Heterocyclic tachykinin receptor antagonists
FR2729952B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
JP3825472B2 (ja) * 1995-03-15 2006-09-27 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニストとしての複素環式の置換されたピペラジノン誘導体
US6294537B1 (en) * 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
KR100414321B1 (ko) * 1995-04-13 2004-02-18 아벤티스 파마슈티칼스 인크. 타치키닌수용체길항활성을갖는신규한치환된피페라진유도체
US5716970A (en) * 1995-04-27 1998-02-10 Pharmacia & Upjohn Company Diuretic compound
GB9508786D0 (en) 1995-04-29 1995-06-21 Zeneca Ltd Substituted heterocycles
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
CA2223239A1 (en) * 1995-06-06 1996-12-12 Schering Corporation Substituted benzene-fused hetero- and carbocyclics as neurokinin antagonists
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US5892039A (en) * 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
HU224225B1 (hu) 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
CA2246727C (en) * 1996-02-21 2002-04-23 Hoechst Marion Roussel, Inc. Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
NZ330909A (en) * 1996-02-21 2001-04-27 Aventis Pharma Inc Substituted N-methyl-N-(4-(4-1H-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
IL129430A0 (en) * 1996-10-28 2000-02-17 Schering Corp Substituted arylalkylamines as neurokinin antagonists
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) * 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5977139A (en) * 1996-12-15 1999-11-02 Hoechst Marion Roussel, Inc. Carboxysubstituted cyclic carboxamide derivatives
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
CA2278309A1 (en) * 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
TR200001437T2 (tr) * 1997-11-21 2000-10-23 Schering Corporation Nörokinin muhasımlar olarak eşdeğer edilen oksimler.
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US6316445B1 (en) 1998-05-15 2001-11-13 Aventis Pharmaceuticals Inc. Carboxy substituted acylic carboxamide derivatives
FR2779429B1 (fr) * 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9922519D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
FR2784377B3 (fr) * 1998-10-09 2000-11-17 Sanofi Sa Nouveaux composes derives d'ureidopiperidine, antagonistes selectifs des recepteurs nk3 humains, procede pour leur obtention et compositions pharmaceutiques les contenant
US6063926A (en) * 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
US6433174B1 (en) * 1998-12-16 2002-08-13 Nippon Kayaku Kabushiki Kaisha Process for producing novel naphthyridine derivatives
CA2346933A1 (en) * 1998-12-18 2000-06-22 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140086A4 (en) * 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
EP1158980B1 (en) * 1998-12-18 2005-08-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
EP1241164B1 (en) * 1999-12-24 2004-05-06 Mitsubishi Rayon Co., Ltd. Process for preparation of tetrahydropyranyloxyamines
EP1296978A2 (en) 2000-06-30 2003-04-02 Bristol-Myers Squibb Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US6511994B2 (en) * 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
WO2002076929A1 (en) 2001-03-21 2002-10-03 Pharmacopeia, Inc. Aryl and biaryl compounds having mch modulatory activity
WO2002083134A1 (en) 2001-04-12 2002-10-24 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
AU2002259147A1 (en) 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
MY141661A (en) * 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DZ3292A1 (fr) * 2001-09-13 2005-05-14 Solvay Pharm Gmbh Nouveaux composes de type 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]piperazine, methodes pour les preparer et medicaments renfermant cescomposes
US6969718B2 (en) * 2001-10-17 2005-11-29 Schering Corporation 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA06001738A (es) 2003-08-15 2006-05-12 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3.
CA2618340C (en) 2005-08-15 2013-11-19 F.Hoffmann-La Roche Ag Piperidine and piperazine derivatives as p2x3 antagonists
US7592344B2 (en) * 2005-11-30 2009-09-22 Solvay Pharmaceuticals Gmbh NK1 and NK2-antagonists and compositions and methods of using the same
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
WO2007136323A1 (en) * 2006-05-18 2007-11-29 Albireo Ab A novel process suitable for large-scale production of phenyl propan derivatives of formula i
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant
CZ2009385A3 (cs) * 2009-06-16 2010-07-28 Zentiva, K. S. Zpusob výroby (S)-4-methylamino-3-(3,4-dichlorfenyl)butan-1-olu
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL254248A (ko) * 1959-07-29
BE701994A (ko) * 1966-07-29 1968-01-02
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
AT376669B (de) * 1982-11-26 1984-12-27 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thienylessigsaeureamid-derivate und pharmazeutisch vertraeglicher saeureadditionssalze davon
ZA842753B (en) * 1983-05-18 1984-11-28 Upjohn Co 2-dihydropyrrolyl-cycloalkyl-amide analgesics
US4920116A (en) * 1985-06-28 1990-04-24 Schering A.G. N-(aminoalkyl)-substituted(N or C alkyl)-aryl-4(methylsulfonylamino)benzamides
US4751327A (en) * 1985-06-28 1988-06-14 Xerox Corporation Photoconductive imaging members with unsymmetrical squaraine compounds
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
EP0261842B1 (en) * 1986-09-17 1990-11-22 Dr. Lo. Zambeletti S.p.A. N1-acylated-(1-(phenyl or benzyl))-1,2-ethylene diamines
FR2613719B1 (fr) * 1987-04-10 1991-03-22 Sanofi Sa Derives aromatiques, leur preparation et leur utilisation comme antimicrobiens
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
HU211893A9 (en) 1995-12-28
IL99320A0 (en) 1992-07-15
PT98849B (pt) 1999-02-26
LV10606A (lv) 1995-04-20
AU8354291A (en) 1992-03-12
PL167994B1 (pl) 1995-12-30
HK1005290A1 (en) 1998-12-31
RU2070196C1 (ru) 1996-12-10
UA27224C2 (uk) 2000-08-15
SG47703A1 (en) 1998-04-17
FI914174A (fi) 1992-03-06
EP0474561B1 (fr) 1998-12-09
CS272491A3 (en) 1992-03-18
FI98457C (fi) 1997-06-25
HU222351B1 (hu) 2003-06-28
EP0474561A1 (fr) 1992-03-11
FI914174A0 (fi) 1991-09-04
DE69130597D1 (de) 1999-01-21
NO913469L (no) 1992-03-06
IL99320A (en) 1995-07-31
CA2050639A1 (en) 1992-03-06
ES2127722T3 (es) 1999-05-01
PT98849A (pt) 1992-07-31
ATE174332T1 (de) 1998-12-15
CA2050639C (en) 1997-12-02
KR100194823B1 (ko) 1999-06-15
US5236921A (en) 1993-08-17
BR9103802A (pt) 1992-05-19
NO913469D0 (no) 1991-09-04
AU657272B2 (en) 1995-03-09
NO177226B (no) 1995-05-02
DE69130597T2 (de) 1999-05-20
IE913082A1 (en) 1992-03-11
DK0474561T3 (da) 1999-08-16
HUT59098A (en) 1992-04-28
NO177226C (no) 1995-08-09
JPH04261155A (ja) 1992-09-17
US5350852A (en) 1994-09-27
FI98457B (fi) 1997-03-14
PL291618A1 (en) 1992-08-24
NZ239661A (en) 1994-06-27
LV10606B (en) 1996-04-20
CZ285994B6 (cs) 1999-12-15
JP2620435B2 (ja) 1997-06-11
GR3029435T3 (en) 1999-05-28
MY142065A (en) 2010-08-30

Similar Documents

Publication Publication Date Title
KR920006314A (ko) 아릴알킬아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR920021511A (ko) 신규의 n-알킬렌피페리디노 화합물 및 이의 거울상 이성질체 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR910009684A (ko) 방향족 아민 화합물, 이의 제조방법 및 이들의 존재하는 약제학적 조성물
KR910006277A (ko) N-치환된-4-피리미딘아민 및 피리미딘디아민, 이의 제조방법 및 약제로서의 이의 용도
KR920004341A (ko) 술폰아미드 유도체
KR970704702A (ko) 치환된 피리미딘 화합물 및 그의 용도(Substituted Pyrimidine Compounds and Their Use)
KR920021523A (ko) 신규한 우레아 유도체, 이의 제조 방법 및 이들을 함유하는 약제학적 조성물
KR930017905A (ko) 신규 아자인돌, 그의 제조방법 및 이를 함유하는 의약품
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
CA2394086A1 (fr) Derives de 4-aminopiperidine et leur utilisation en tant que medicament
NZ337118A (en) 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same useful in treating or preventing arteriosclerotic and/or hyper-lipemia disease, pancreatitis, obesity, hypercholesterolemia and hypertriglyceridemia.
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
KR860004032A (ko) 피페라진 화합물의 제조방법
KR970704710A (ko) 트리아졸 화합물 및 도파민 D₃리간드로서의 그의 용도(Triazole Compounds and Their Use as Dopamine-D₃-Ligands)
KR890003742A (ko) 카르바모일키롤리돈 유도체 및 노인성 치매용 약제
KR870010067A (ko) 신규의 디포스폰산 화합물, 이들의 제조 방법 및 이들을 함유하는 제약조성물
KR960701048A (ko) 이소옥사졸리딘디온 유도체 및 그의 용도(isoxazolidinedione derivative and use thereof)
KR900007790A (ko) 항-아테롬성 동맥경화증성 디아릴 화합물
FI860878A0 (fi) Aminosyraderivat och foerfarande foer deras framstaellning.
KR900018065A (ko) 벤조시클로알칸 유도체 및 그의 제조방법
IL106445A0 (en) 4-substituted 1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
ATE233239T1 (de) Enantiomere von carbazolderivaten als 5-ht1- ähnliche agonisten
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR890016017A (ko) 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20101228

Year of fee payment: 13

EXPY Expiration of term